Claims

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

A is a bicyclic 6,5 or 6,6 aromatic or heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6}alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6}alkoxy, arylC_{1-6}alkoxy, C_{1-6}alkylthio, C_{1-6}alkoxyC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, C_{1-6}alkylsulfonamido, C_{1-6}alkylamido, arylsulfonamido, arylcarboxamido, aroyl, arylC_{1-6}alkanoyl, and a group Ar^1-B, wherein B represents a single bond, O, S or CH_2 and Ar^1 represents a phenyl or a monocyclic heteroaromatic group, said Ar^1 group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C_{1-6}alkyl, C_{1-6}alkoxy or C_{1-6}alkanoyl;

R1 is hydrogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl or arylC_{1-6}alkyl;

R2 is independently halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;

p is 0, 1 or 2;

R3 (a) is a group -(R4)r wherein R4 is selected from the group consisting of: C_{1-6}alkyl, halogen, hydroxy, oxo, cyano, nitro, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, arylC_{1-4}alkoxy, C_{1-4}alkylthio, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfonyloxy, C1$_{-4}$alkylsulfonylC_{1-4}alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-4}alkyl, C_{1-4}alkylsulfonamido, C_{1-4}alkylamido, C_{1-4}alkylsulfonamidoC_{1-4}alkyl, C_{1-4}alkylamidoC_{1-4}alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-4}alkyl, arylcarboxamidoC_{1-4}alkyl, aroyl, aroylC_{1-4}alkyl, arylC_{1-4}alkanoyl, C_{1-4}acyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl and a group R30R31N- (where each of R30 and R31 independently represents a hydrogen atom or a C_{1-4}alkyl group or where appropriate R30R31

forms part of a C_{3-6}azacyloalkane or C_{3-6}(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected from halogen, oxo, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy; or

(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;

X is CH, N or C;

⎓ represents a single bond when X is CH or N; and ⎓ represents a double bond when X is C;

q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)- or a group



wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)-, -C(=O)-, -C(=CH_2)-, oxygen, or a methylene group optionally substituted by one or two groups selected from halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;

provided that when A is naphthyl, 5,6,7,8-tetrahydronaphthyl or 2,3-dihydoindene, Z is not -(CH_2CH(OH))- , -(CH_2CH_2CH(OH))- or -(CH_2C(=O) .

2. A compound as claimed in claim 1, wherein A is a bicyclic 6,5 or 6,6 heteroaromatic group.

3. A compound of formula (Ia) or a pharmaceutically acceptable salt thereof:



(Ia)

wherein:

A is a bicyclic 6,5 or 6,6 heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are

selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6}alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6}alkoxy, arylC_{1-6}alkoxy, C_{1-6}alkylthio, C_{1-6}alkoxyC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, C_{1-6}alkylsulfonamido, C_{1-6}alkylamido, Arylsulfonamido, arylcarboxamido, aroyl, arylC_{1-6}alkanoyl, and a group Ar^1-B, wherein B represents a single bond, O, S or CH_2 and Ar^1 represents a phenyl or a monocyclic heteroaromatic group, said Ar^1 group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C_{1-6}alkyl, C_{1-6}alkoxy or C_{1-6}alkanoyl;

R1 is hydrogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl or arylC_{1-6}alkyl;

R2 is independently halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;

p is 0, 1 or 2;

R3 (a) is a group -(R4)r wherein R4 is selected from the group consisting of: C_{1-6}alkyl, halogen, hydroxy, oxo, cyano, nitro, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, arylC_{1-4}alkoxy, C_{1-4}alkylthio, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfonyloxy, C1-4alkylsulfonylC_{1-4}alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-4}alkyl, C_{1-4}alkylsulfonamido, C_{1-4}alkylamido, C_{1-4}alkylsulfonamidoC_{1-4}alkyl, C_{1-4}alkylamidoC_{1-4}alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-4}alkyl, arylcarboxamidoC_{1-4}alkyl, aroyl, aroylC_{1-4}alkyl, arylC_{1-4}alkanoyl, C_{1-4}acyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl and a group R30R31N- (where each of R30 and R31 independently represents a hydrogen atom or a C_{1-4}alkyl group or where appropriate R30R31 forms part of a C_{3-6}azacyloalkane or C_{3-6}(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected from halogen, oxo, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy; or

(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;

X is CH, N or C;

⎓ represents a single bond when X is CH or N; and ⎓ represents a double bond when X is C;

q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)- or a group



wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)-, -C(=O)-, -C(=CH_2)-, oxygen, or a methylene group optionally substituted by one or two groups selected from halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;
provided that when A is naphthyl, 5,6,7,8-tetrahydronaphthyl or 2,3-dihydoindene, Z is not -(CH_2CH(OH))- , -(CH_2CH_2CH(OH))- or -(CH_2C(=O) .

4. A compound as claimed in any of claims 1 to 3, wherein R1 is hydrogen or methyl.

5. A compound as claimed in any of claims 1 to 4, wherein R3 is methyl.

6. A compound as claimed in any of claims 1 to 5, wherein X is CH or N and ------- is a single bond.

7. A compound as claimed in any of claims 1 to 6, wherein q is 1.

8. A compound as claimed in any of claims 1 to 7, wherein Z is -(CH_2)$_2$- or -(CH_2)3-.

9. A compound as claimed in any of claims 1 to 8 , wherein A is indolyl, quinolyl, quinazolinyl or 2,3-dihydrobenzodioxinyl.

10. A compound as claimed in any of claims 1 to 9, wherein A is substituted by 1 to 4 substituents selected from the group consisting of halogen (particularly fluoro or chloro), C_{1-6}alkyl (particularly methyl, ethyl and propyl), cyano, CF_3, C_{1-6}alkoxy (particularly methoxy, ethoxy or isopropoxy) or C_{1-6}alkanoyl.

11. A compound as claimed in any of claims 1 to 10, wherein A is selected from the group consisting of 5-quinolyl(2-Me), 5-quinolyl(2-Me, 7-Cl), 5-quinolyl(2-Me, 7-F) and 5-quinazolinyl(2-Me), 5-quinolyl(2-Me, 7-Me), 5-dihydrobenzo[1,4]dioxinyl, 8-quinolyl(6-methoxy), 8-quinolyl, 4-indolyl and 4-indolyl(2-Me).

12. A compound as claimed in claim 1, which is selected from the group consisting of:
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(2,7-Dimethylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-[2-(4-Quinolin-4-ylpiperazin-1-yl)ethyl]-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one

6-{2-[4-(2,3-Dihydrobenzo[1,4]dioxin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(6-Methoxyquinolin-8-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-[2-(4-Quinolin-8-yl)piperazin-1-yl)ethyl]-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(1*H*-Indol-4-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-7-fluoro-4*H*-benzo[1,4]oxazin-3-one
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4*H*-benzo[1.4]oxazin-3-one
6-{1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[3-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[2-Methyl-4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)-3,6-dihydro-2*H*-pyridin-1-yl]ethyl}-4H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)piperidin-1-yl]ethyl}-4-H-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinazolin-5-yl)-[1,4]diazepan-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propyl}-4*H*-benzo[1,4]-oxa-zin-3-one
6-{3-[4-(7-Fluoro-2-methylquinolin-5-yl)piperazin-1-yl]-propyl}-4*H*-benzo-[1,4]oxazin-3-one
6-{3-[4-(2-Methylquinolin-5-yl)-piperazin-1-yl]-propanoyl}-4*H*-benzo[1,4]-oxa-zin-3-one
6-{1-Hydroxy-3-[4-(2-methylquinolin-5-yl)-piperazin-1-yl]-propyl}-4*H*-benzo-[1,4]oxazin-3-one
6-{(E)-3-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]propenyl}-4*H*-benzo[1,4]-oxa-zin-3-one
6-{4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]butyl}-4*H*-benzo[1,4]oxazin-3-one
6-{4-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]-cyclohex-1-enyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{4-[4-(2-Methylquinazolin-5-yl)piperazin-1-yl]butyl}-4*H*-benzo[1,4]oxazin-3-one
6-{2-[4-(2-Methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4-H-benzo[1,4]oxazin-3-one
4-Methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethoxy}-4-H-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one

6-{2-[4-(7-fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]oxazin-3-one
7-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4*H*-benzo[1,4]oxazin-3-one
6-{1-Hydroxy-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{1-Methoxy-3-[4-(2-methylquinolin-5-yl)piperazin-1-yl]propyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{2-[4-(2-Methyl-1*H*-indol-4-yl)piperazin-1-yl]-ethyl}-4*H*-benzo-[1,4]oxazin-3-one
6-{2-[4-(5,6,7,8-Tetrahydronaphthalen-1-yl)piperazin-1-yl]ethyl}-4*H*-benzo-[1,4]oxazin-3-one
6-[2-(4-Naphthalen-1-ylpierazin-1-yl)ethyl]-4*H*-benzo[1.4]oxazin-3-one hydrochloride salt
6-{1-Fluoro-2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{1-Fluoro-3-[4-(2-methylquinolin-5-yl)piperazin-1-yl]propyl}-4*H*-benzo[1,4]-oxazin-3-one
5-Fluoro-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]-oxazin-3-one
5-Fluoro-4-methyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4-methyl-4*H*-benzo-[1,4]-oxazin-3-one
4-Ethyl-6-{2-[4-(2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1,4]-oxazin-3-one
6-{2-[4-(7-Fluoro-2-methylquinolin-5-yl)piperazin-1-yl]ethyl}-4-methyl-4*H*-benzo-[1,4]-oxazin-3-one
6-{1-(Methyloxy)-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{1-Amino-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
N-[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]acetamide
6-{1-(Methylamino)-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(phenyloxy)ethyl]-2H-1,4-benzoxazin-3(4H)-one
[2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]formamide
6-{1-Hydroxy-1-methyl-3-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one
6-{1-Hydroxy-1-methyl-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{(1E)-1-Methyl-3-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]-1-propen-1-yl}-2H-1,4-benzoxazin-3(4H)-one
6-(1-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}ethenyl)-2H-1,4-benzoxazin-3(4H)-one
6-(1-{[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]methyl}ethenyl)-2H-1,4-benzoxazin-3(4H)-one
2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]-1-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl acetate
6-{1-Hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{[4-(8-Quinolinyl)-1-piperazinyl]methyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[(1*S*,4*S*)-5-(2-Methyl-5-quinolinyl)-2,5-diazabicyclo[2.2.1]hept-2-yl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(2-Quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{3-[4-(2-Quinolinyl)-1-piperazinyl]propyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(6-Chloro-2-quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(6-Nitro-2-quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(7-Methyl-1,8-naphthyridin-4-yl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(1,6-Naphthyridin-5-yl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(2-Phenylquinolin-5-yl)piperazin-1-yl]ethyl}-4*H*-benzo[1.4]oxazin-3-one
6-{[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{1-Fluoro-2-[4-(7-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-Fluoro-6-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-Fluoro-6-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
8-Fluoro-6-{1-hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-Fluoro-6-{1-fluoro-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-Fluoro-6-{2-[4-(7-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-Fluoro-6-{[4-(7-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
8-Fluoro-6-{2-[4-(7-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{[4-(8-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one

6-{2-[4-(8-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(8-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
4-Methyl-8-{2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
8-{2-[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-7-fluoro-2H-1,4-benzoxazin-3(4H)-one
6-{2-[(2S)-2-Methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[(2R)-2-Methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(2,3-dihydro-1,4-benzodioxin-6-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(3,4-dihydro-2H-1,5-benzodioxepin-7-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-bromo-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{3-[4-(7-bromo-1H-indol-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(1-isoquinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
ethyl 5-{4-[2-(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)ethyl]-1-piperazinyl}-1-benzofuran-2-carboxylate
6-{2-[4-(1,2-dihydro-5-acenaphthylenyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(5-fluoro-1H-indol-3-yl)-1-piperidinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(5-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(6-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-chloro-1H-indol-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{3-[4-(1H-pyrrolo[2,3-b]pyridin-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one
6-{3-[4-(5-chloro-1H-indol-4-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(5-methylthieno[2,3-d]pyrimidin-4-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
6-({2-[4-(2-methyl-5-quinazolinyl)-1-piperazinyl]ethyl}oxy)-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-Chloro-2-methylquinolin-5-yl)piperazin-1-yl]ethanoyl}-4*H*-benzo[1.4]oxazin-3-one
6-{2-[4-(7-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-Chloro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-fluoroethyl}-2H-1,4-benzoxazin-3(4H)-one

6-{3-[4-(2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-yl)-1-piperazinyl]propyl}-2H-1,4-benzoxazin-3(4H)-one
6-{2-[4-(2,2-dimethyl-2,3-dihydro-1-benzofuran-7-yl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3(4H)-one
4-Methyl-6-{[4-(1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-3,6-dihydro-1(2*H*)-pyridinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{1-hydroxy-2-[4-(1*H*-pyrrolo[2,3-*b*]pyridin-3-yl)-3,6-dihydro-1(2*H*)-pyridinyl]ethyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{[4-(2-Methyl-5-quinolinyl)-1-piperazinyl]methyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
4-methyl-6-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-3,4-dihydro-2*H*-1,4-benzoxazin-2-one
4-Methyl-6-(1-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]methyl}ethenyl)-3,4-dihydro-2*H*-1,4-benzoxazin-2-one
6-(2-Hydroxy-1-{[4-(2-methyl-5-quinolinyl)-1-piperazinyl]methyl}ethyl)-4-methyl-3,4-dihydro-2*H*-1,4-benzoxazin-2-one
6-{[4-(6-fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{1-Hydroxy-2-[4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{[4-(8-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(8-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]acetyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-4-methyl-2*H*-1,4-benzoxazin-3(4*H*)-one
4-Methyl-6-{2-[4-(2-methyl-5-quinolinyl)hexahydro-1*H*-1,4-diazepin-1-yl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
4-Methyl-6-{2-[3-methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(8-Chloro-2-methylquinolin-5-yl)-piperazine-1-yl]-ethyl}-4-methyl-4H-benzo[1,4]oxazine-3-one
6-{2-[4-(8-Fluoro-2-methyl-quinolin-5-yl)-piperazine-1-yl]-ethyl}-4-methyl-4H-benzo[1,4]oxazine-3-one
6-{2-[4-(2-Methyl-1H-indol-4-yl)piperazin-1-yl]ethanoyl}-4*H*-benzo[1.4]oxazin-3-one
6-{1-Hydroxy-2-[4-(2-methyl-1H-indol-4-yl)piperazinyl]ethyl}-2*H*-benzo[1.4]oxazin-3-one
6-{1-Fluoro-2-[4-(2-methyl-1H-indol-4-yl)piperazinyl]ethyl}-2*H*-benzo[1.4]oxazin-3-one

6-{2-[4-(7-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2-H-1,4-benzoxazin-3-(4H)-one
6-{2-[4-(2-Methyl-5quinolinyl)-1-piperadinyl}-ethanoyl}-2*H*-1,4-benzoxazin-3(4H)-one
6-{1-Hydroxy-2-[4-(2-methyl-5quinolinyl)-1-piperadinyl}-ethyl}-2*H*-1,4-benzoxazin-3(4H)-one
6-{2-[4-(7-Fluoro-2-methylquinolin-5-yl)piperidin-1-yl]ethyl}-4-H-benzo[1,4]-oxazin-3-one
6-{2-[4-(6-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]-1-hydroxyethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6{2-[4(8-Fluoro-2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3-(4H)-one
6-{2-[4-2-Quinoxalinyl)-1-piperazinyl]ethyl}-2H-1,4-benzoxazin-3-(4H)-one
4-Methyl-8-{2-[(2*R*)-2-methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
4-Methyl-8-{2-[(2*S*)-2-methyl-4-(2-methyl-5-quinolinyl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(7-Chloro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(7-Fluoro-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
6-{2-[4-(7-Bromo-2,3-dihydro-1,4-benzodioxin-5-yl)-1-piperazinyl]ethyl}-2*H*-1,4-benzoxazin-3(4*H*)-one
8-{4-[2-(3-Oxo-3,4-dihydro-2*H*-1,4-benzoxazin-6-yl)ethyl]-1-piperazinyl}-2,3-dihydro-1,4-benzodioxin-6-carbonitrile
and pharmaceutically acceptable salts thereof.

13. A process for the preparation of a compound of formula (I) as defined in claim 1 or a pharmaceutically acceptable salt thereof, which process comprises:

(a) reacting a compound of formula (II):



(II)

wherein R1, R2, p and Z are as defined in formula (I), and L is a leaving group, with a compound of formula (III):



(III)

wherein A, R3, ---, X and q are as defined in formula (I); or

(b) the reduction and concominant cyclisation of a compound of formula (IV):



(IV)

in which A, X, R3, ---, q and Z are as defined in formula (I);

and optionally thereafter for each of process (a) or (b):

- removing any protecting groups, and/or
- converting a compound of formula (I) into another compound of formula (I), and/or
- forming a pharmaceutically acceptable salt.

14. A compound of formula (I) or formula (Ia) as defined in any of claims 1 to 12 or a pharmaceutically acceptable salt thereof, for use in therapy.

15. A pharmaceutical composition, which comprises a compound of formula (I) or formula (Ia) as defined in any of claims 1 to 12 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier or excipient.

16. A process for preparing a pharmaceutical composition as defined in claim 15, the process comprising mixing a compound of formula (I) or formula (Ia) as defined in any of claims 1 to 12 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier or excipient.

17. A compound of formula (Ib) or a pharmaceutically acceptable salt thereof:



(Ib)

wherein:

A is a bicyclic 6,5 or 6,6 aromatic or heteroaromatic group which is optionally substituted by 1 - 4 substituents, which substituents may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, C_{1-6}alkyl, trifluoromethanesulfonyloxy, pentafluoroethyl, C_{1-6}alkoxy, arylC_{1-6}alkoxy, C_{1-6}alkylthio, C_{1-6}alkoxyC_{1-6}alkyl, C_{3-7}cycloalkylC_{1-6}alkoxy, C_{1-6}alkanoyl, C_{1-6}alkoxycarbonyl, C_{1-6}alkylsulfonyl, arylsulfonyl, arylsulfonyloxy, C_{1-6}alkylsulfonamido, C_{1-6}alkylamido, arylsulfonamido, arylcarboxamido, aroyl, arylC_{1-6}alkanoyl, and a group Ar^1-B, wherein B represents a single bond, O, S or CH_2 and Ar^1 represents a phenyl or a monocyclic heteroaromatic group, said Ar^1 group being optionally substituted by 1 - 3 substituents, which may be the same or different, and which are selected from the group consisting of a halogen, hydroxy, cyano, trifluoromethyl, C_{1-6}alkyl, C_{1-6}alkoxy or C_{1-6}alkanoyl;

R1 is hydrogen, C_{1-6}alkyl, haloC_{1-6}alkyl, C_{3-7}cycloalkyl, C_{3-7}cycloalkylC_{1-6}alkyl, C_{3-6}alkenyl, C_{3-6}alkynyl or arylC_{1-6}alkyl;

R2 is independently halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;

p is 0, 1 or 2;

R3 (a) is a group -(R4)r wherein R4 is selected from the group consisting of: C_{1-6}alkyl, halogen, hydroxy, oxo, cyano, nitro, C_{1-4}alkoxy, haloC_{1-4}alkyl, haloC_{1-4}alkoxy, arylC_{1-4}alkoxy, C_{1-4}alkylthio, hydroxyC_{1-4}alkyl, C_{1-4}alkoxyC_{1-4}alkyl, C_{3-6}cycloalkyl, C_{3-6}cycloalkylC_{1-4}alkoxy, C_{1-4}alkanoyl, C_{1-4}alkoxycarbonyl, C_{1-4}alkylsulfonyl, C_{1-4}alkylsulfonyloxy, C1-4alkylsulfonylC_{1-4}alkyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-4}alkyl, C_{1-4}alkylsulfonamido, C_{1-4}alkylamido, C_{1-4}alkylsulfonamidoC_{1-4}alkyl, C_{1-4}alkylamidoC_{1-4}alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-4}alkyl, arylcarboxamidoC_{1-4}alkyl, aroyl, aroylC_{1-4}alkyl, arylC_{1-4}alkanoyl, C_{1-4}acyl, aryl, arylC_{1-4}alkyl, C_{1-4}alkylaminoC_{1-4}alkyl and a group R30R31N- (where each of R30 and R31 independently represents a hydrogen atom or a C_{1-4}alkyl group or where appropriate R30R31 forms part of a C_{3-6}azacyloalkane or C_{3-6}(2-oxo)azacycloalkane ring), and r is 0, 1, 2 or 3; or

(b) forms a bridge across the ring, the bridge consisting of a chain of 1 to 3 atoms, the bridge being optionally substituted by one, two or three groups selected

from halogen, oxo, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy; or

(c) is a chain of 1 to 3 atoms optionally substituted by halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy, the other end of the chain being attached to an available carbon atom in Z;

X is CH, N or C;

------ represents a single bond when X is CH or N; and ------ represents a double bond when X is C;

q is 0, 1 or 2, wherein when q is 0, X is not N; and

Z is attached to the 6-position or the 8-position of the benzoxazinone group and is a 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)- or a group



wherein m and n are independently 0, 1 or 2, and Y is a single bond, 3 to 7 membered cycloalkylene group, 3 to 7 membered cycloalkenylene group, -(CH=CH)-, -C(=O)-, -C(=CH_2)-, oxygen, or a methylene group optionally substituted by one or two groups selected from halogen, C_{1-6}alkyl, cyano, haloC_{1-6}alkyl, C_{1-6}alkanoyl, C_{1-6}alkoxy or hydroxy;

for use in the treatment of a serotonin-related disorder.

18. A compound as claimed in claim 17, wherein the disorder is depression or anxiety.

19. Use of a compound as defined in claim 17 in the preparation of a medicament for the treatment of a serotonin-related disorder.

20. The use as claimed in claim 19, wherein the disorder is depression or anxiety.

21. A method of treatment of a serotonin-related disorder, comprising administering to a mammal in need thereof a safe and effective amount of a compound as defined in claim 17.

22. The method as claimed in claim 21, wherein the disorder is depression or anxiety.